Related by context. All words. (Click for frequent words.) 68 MAGE A3 ASCI 67 neratinib 67 alvespimycin 67 HGS ETR2 67 CTAP# Capsules 66 PXD# 66 Zemplar Capsules 66 trastuzumab DM1 T DM1 66 preclinical efficacy 66 INCB# [001] 66 Bezielle 66 YONDELIS 65 Neuvenge 65 Phase #/#a trial 65 relapsed MM 65 Telintra 65 GRNVAC1 65 trastuzumab emtansine T DM1 65 PEG SN# 65 randomized discontinuation trial 65 teriflunomide 64 HDL Selective Delipidation 64 HuMax EGFr 64 CYT# potent vascular disrupting 64 enzastaurin 64 Pralatrexate 64 motesanib 64 Vitaxin 64 Azedra 64 STRIDE PD 64 Exelixis compounds 64 depsipeptide 64 evaluating tivozanib 64 dacetuzumab 64 Phase Ib II 64 oral picoplatin 64 velafermin 64 MGd 64 SAR# [004] 64 huC# DM4 64 sipuleucel T 64 assessing T DM1 64 MEND CABG 64 dose escalation clinical 64 CD# CEA 64 Zevalin consolidation 64 Phase #b/#a clinical 64 PI3K/Akt pathway inhibitor 64 mg/m2 cohort 64 cilengitide 64 PANVAC VF 64 evaluating mipomersen 64 Sym# 63 antibody MAb 63 IMA# 63 riociguat 63 OncoVEX GM CSF 63 OvaRex R 63 forodesine 63 demonstrated antitumor activity 63 Traficet EN 63 CCX# 63 myeloproliferative diseases 63 HER2 positive metastatic breast 63 Apoptone 63 Neuradiab 63 investigational monoclonal antibody 63 pain palliation 63 PRIMO CABG 63 dose escalation phase 63 Virulizin ® 63 Phase IIb III 63 mertansine 63 Phase Ib study 63 dose cohort 63 EGFR HER2 63 fosbretabulin 63 CR# vcMMAE 63 bavituximab monotherapy trial 63 ovarian carcinoma 63 investigational humanized monoclonal antibody 63 Hsp# Inhibitor 63 elotuzumab 63 samalizumab 63 HCV protease inhibitors 63 axitinib 63 RGB # 63 ENMD # 63 colorectal liver metastases 63 p# biomarker 63 HuMax CD4 63 pertuzumab 63 metastatic RCC 63 evaluating REVLIMID 62 autologous cellular immunotherapy 62 XL# anticancer compounds 62 relapsed ovarian cancer 62 Trofex TM 62 Xcellerated T Cells 62 galiximab 62 rALLy trial 62 BRIM3 62 EFAPROXYN 62 metastatic castration resistant 62 proteasome inhibitor 62 Quinamed 62 Panzem R NCD 62 tramiprosate Alzhemed TM 62 Lenocta 62 initiate Phase 1b 62 PROSTVAC TM 62 Aplidin 62 BR.# 62 Tarceva TM 62 pomalidomide 62 UPLYSO 62 MEK inhibitor RDEA# 62 IMPACT DCM 62 Vascugel ® 62 HCD# [002] 62 Glufosfamide 62 phase IIb clinical 62 vidofludimus 62 evaluating satraplatin 62 PSMA ADC 62 mapatumumab 62 Bayer HealthCare Onyx Pharmaceuticals 62 ganetespib 62 ongoing Phase 1b 62 ThermoDox ® clinical 62 tanespimycin 62 HCV RESPOND 2 62 adecatumumab 62 Aflibercept 62 Ophena 62 Vicinium TM 62 TELCYTA 62 maximally tolerated dose 62 recurrent glioblastoma multiforme 62 adecatumumab MT# 62 acyclovir Lauriad R 62 recurrent NSCLC 62 telomerase therapeutic 62 Ceplene/IL-2 62 cMET 62 antiangiogenic therapy 62 Phase Ib clinical 62 nonclinical studies 62 zanolimumab 62 cannabinor 62 candidate CRLX# 62 orally administered inhibitor 62 MKC# MT 62 GRN#L 62 Octreolin 62 ZYBRESTAT fosbretabulin 62 BCIRG 62 talactoferrin 62 NP2 Enkephalin 62 ToGA 62 TBC# 62 Archexin 62 Hyphanox 62 registrational 62 MEND CABG II 62 OncoVEX 62 TACI Ig 62 rALLy clinical trial 62 favorable pharmacokinetic profile 62 ospemifene 62 intravesical therapy 62 AA Amyloidosis 62 indibulin 62 edifoligide E2F Decoy 62 targeting CD# 62 CEQ# 61 HCV SPRINT 61 trastuzumab DM1 61 tolerability profiles 61 Prostate AdenoCarcinoma Treatment 61 HGS ETR1 61 XL# XL# XL# XL# 61 Epratuzumab 61 XL# SAR# 61 recurrent metastatic 61 ZK EPO 61 heavily pretreated patients 61 ® bortezomib 61 crizotinib PF # 61 Phase IIB 61 refractory multiple myeloma 61 AP# [003] 61 metastatic pancreatic 61 Fibrillex TM 61 SUTENT ® 61 TASKi3 61 Sipuleucel T 61 Zenvia ™ 61 APPRAISE 61 pharmacokinetic pharmacodynamic 61 refractory colorectal cancer 61 CRLX# 61 cytokine refractory 61 novel VDA molecule 61 BRIM2 61 epithelial tumors 61 ZOLINZA 61 LHRH receptor positive 61 oral ridaforolimus 61 Faslodex 61 K ras mutations 61 Phase 1a clinical 61 Androxal TM 61 DASISION 61 farletuzumab 61 XL# XL# 61 Canvaxin TM 61 imetelstat GRN#L 61 lintuzumab SGN 61 Aplidin R 61 CTA# Injection 61 volociximab 61 AVOREN 61 metastatic CRC 61 glufosfamide 61 IMC #B 61 Romiplostim 61 GVAX Pancreas Vaccine 61 ponatinib 61 modified glutathione analog 61 romidepsin 61 Vectibix panitumumab 61 liposomal doxorubicin 61 HER2 overexpression 61 interferon gamma 1b 61 oral prodrug 61 NSABP B 61 relapsed refractory multiple myeloma 61 SABCS 61 Allovectin 7 ® 61 BrachySil TM 61 Xanafide 61 radiation sensitizer 61 XmAb# 61 Darinaparsin 61 multicenter Phase II 61 pediatric malignancies 61 thalidomide Thalomid 61 recurrent glioma 61 randomized Phase 2b 61 postmenopausal osteoporotic women 61 EpCAM 61 Phase IIIb clinical 61 UVIDEM 61 demonstrated clinically meaningful 61 Allovectin 7 61 refractory metastatic 61 ELACYT 61 taxane resistant 61 PDX pralatrexate 61 R roscovitine 61 metastatic neuroendocrine tumors 61 elacytarabine 61 OvaRex MAb 61 EndoTAG TM -1 61 APOPTONE 61 pharmacokinetic PK 61 selective androgen receptor modulator 61 CBLC# 61 angiographic outcomes 61 ixabepilone 61 prostate cancer CaP 61 telomerase inhibitor drug 61 fallopian tube cancers 61 metaglidasen 61 Symadex 61 GLP toxicology studies 61 AAG geldanamycin analog 61 Vernakalant 61 octreotide implant 61 BiTE antibody MT# 61 ONCONASE R 61 PROSTVAC VF 61 Solazed TM 61 HspE7 61 JAK inhibitors 61 CALGB # [002] 61 huN# DM1 61 Corgentin 61 SinuNase ™ 61 Curaxin CBLC# 61 posaconazole 61 heavily pretreated 61 R sorafenib tablets 61 mRCC 61 SUCCEED trial 61 INSPIRE Trial Phase III 61 oral mTOR inhibitor 60 LymphoStat B belimumab 60 ROCKET AF 60 imatinib therapy 60 selective kinase inhibitor 60 FOLFOX6 chemotherapy regimen 60 Ophena TM 60 RIGScan CR 60 Cloretazine ® 60 lenalidomide Revlimid R 60 sorafenib Nexavar 60 tumor xenograft models 60 imetelstat 60 receptor tyrosine kinase inhibitor 60 AKT inhibitor 60 phase IIb III 60 oral methylnaltrexone 60 phase IIa clinical 60 pralatrexate 60 Azedra ™ 60 EndoTAGTM 1 60 Alocrest 60 Proxinium TM 60 Triapine R 60 kidney urologic 60 MOZOBIL 60 Poly ICLC 60 CIMZIA TM certolizumab pegol 60 erlotinib Tarceva ® 60 trabectedin 60 refractory chronic lymphocytic 60 MGN# 60 pivotal bioequivalence 60 cediranib 60 systemic anaplastic large 60 VEGFR2 inhibitor 60 CLARITY study 60 AVADO 60 midstage clinical 60 fusion enhancers 60 BZL# 60 thorough QT 60 PSN# [002] 60 ruxolitinib 60 Cimzia TM 60 AACR NCI EORTC 60 urinary N telopeptide 60 rALLy 60 CYC# 60 AVERROES 60 gastric carcinoma 60 recurrent GBM 60 Romidepsin 60 TransVax ™ 60 nalbuphine ER 60 non nucleoside HCV 60 randomized Phase IIb 60 tumorigenicity 60 efalizumab 60 DAVANAT 60 bazedoxifene 60 HGS# 60 Phase IIb clinical trials 60 histone deacetylase HDAC inhibitor 60 Solorel TM 60 metastatic renal cell carcinoma 60 HBV infections 60 Xelox 60 LungAlert TM 60 refractory CLL 60 adenoma recurrence 60 pharmacodynamic PD 60 RECORD1 60 oxymorphone ER 60 ISTODAX 60 pharmacodynamic parameters 60 Deforolimus 60 Hodgkin lymphoma HL 60 PD LID 60 MCSP respectively 60 Entereg R 60 Vaxfectin R adjuvant 60 Blinatumomab 60 IL# PE#QQR 60 liposomal formulation 60 NV1FGF 60 AQ4N 60 pharmacodynamic markers 60 Pharmacokinetic parameters 60 ASCO GU 60 sorafenib tablets 60 CARE HF 60 Hepatocellular Carcinoma HCC 60 randomized multicenter Phase III 60 Azedra TM 60 anti EGFR antibody 60 #D#C# 60 NSABP 60 JAK2 inhibitor 60 Tesmilifene 60 HER2 expression 60 EVEREST II 60 TOCOSOL Camptothecin 60 catheter occlusion 60 docetaxel Taxotere ® 60 eTag assays 60 ENESTnd 60 NADiA 60 Pruvel 60 decitabine 60 percutaneous cryoablation 60 TKM ApoB 60 Ceflatonin 60 TORISEL TM 60 ongoing Phase IIIb 60 Temsirolimus 60 oral FTY# 60 SYMMETRY trial 60 polycythemia vera PV 60 mTOR inhibition 60 metastatic HRPC 60 VEGF inhibitors 60 superficial bladder cancer 60 Proellex TM 60 mucinous 60 PIX# [002] 60 lymphoid malignancies 60 ADVEXIN therapy 60 G#DT 60 phase Ib 60 DXL# 60 sunitinib malate 60 metastatic GIST 60 Thorough QT 60 ENABLE Phase 2 60 Val HeFT 60 Hematologic 60 panobinostat 60 AEGR 60 clevidipine 60 castration resistant prostate cancer 60 novel therapeutic antibodies 60 tubulin inhibitor 60 neoadjuvant therapy 60 rindopepimut 60 placebo controlled clinical 60 prospective observational studies 60 novel histone deacetylase 60 cisplatin resistant 60 Tanespimycin 60 randomized controlled multicenter 60 RhuDex ® 60 either acutely decompensated 60 BioNumerik 60 CLORETAZINE TM VNP#M 60 Dextofisopam 60 subcutaneous PRO 60 cytoreductive nephrectomy 60 nab paclitaxel 60 prostate carcinoma 60 CD3 monoclonal antibody 60 Imprime PGG 60 Trofex 60 Pirfenidone 60 PRT# 60 Valortim R 60 human IgG1 monoclonal 60 PrevOnco 59 cell acute lymphoblastic 59 TNF antagonist 59 GVAX 59 Aurexis 59 refractory AML 59 DCVax R 59 Vidofludimus 59 pharmacokinetic PK study 59 Saforis 59 placebo controlled multicenter 59 leukemia AML 59 Elotuzumab 59 haematologic 59 targeted radiotherapeutic 59 PNP inhibitor 59 AGHD 59 histologies 59 pan HDAC inhibitor 59 Phase 1b clinical trials 59 somatostatin analogues 59 IgG1 monoclonal antibody 59 APEX AMI trial 59 PDE# inhibitors 59 hypercalcemia 59 metastatic colorectal 59 adjuvant radiation 59 JAK inhibitor 59 BrachySil 59 recurrent malignant glioma 59 Dacogen injection 59 TELINTRA 59 Hedgehog Pathway Inhibitor 59 ORAL Sync 59 IMGN# 59 Factor VIIa 59 Personalized Immunotherapy 59 Oral NKTR 59 TransVax 59 ER CHOP 59 preclinical pharmacokinetic 59 endocrine therapy 59 Triolex 59 IRX 2 59 Golimumab 59 sapacitabine CYC# 59 Anturol TM 59 noninfectious uveitis 59 papillary renal cell carcinoma 59 dosing cohort 59 prostate cancer AIPC 59 thoracoscopic lobectomy 59 dosing cohorts 59 LY# [003] 59 NOX E# 59 Phase Ib IIa 59 CINQUIL 59 nonsmall cell lung cancer 59 HQK 59 CCX# B 59 refractory acute myeloid 59 Capesaris 59 REVIVE Diabetes 59 candidate TNFerade biologic 59 Diabetic Macular Edema 59 Cloretazine R VNP#M 59 RSR# 59 Randomized Double blind 59 adjuvant colon cancer 59 ACTEMRA TM 59 epigenetic therapies 59 antiangiogenic agent 59 pegylated liposomal doxorubicin 59 PREOS R 59 Ocrelizumab 59 vismodegib 59 GAP #B# 59 ANCHOR trial 59 TKM PLK1 59 CoFactor 59 investigational therapies 59 BAY #-# 59 histone deacetylase inhibitor 59 NO# [002] 59 BLA filing 59 Randomized Phase II 59 iniparib 59 #beta estradiol 59 lomitapide 59 confirmatory clinical 59 BiTE R 59 R lenalidomide 59 gemcitabine cisplatin 59 LibiGel Phase III 59 budesonide foam 59 urocortin 2 59 LBH# 59 AeroLEF TM 59 postoperative chemotherapy 59 cabozantinib 59 GAMMAGARD 59 tolerability pharmacokinetics 59 cervical carcinoma 59 Cerashield 59 LymphoStat B TM 59 ALN TTR 59 TAXUS VI 59 MYTHOS trial 59 PhG alpha 1 59 urate lowering 59 pharmacodynamic properties 59 BCR ABL inhibitors 59 eltrombopag 59 LAB CGRP 59 AtherOx 59 castrate resistant prostate cancer 59 tolevamer 59 monoclonal antibody conjugated 59 gefitinib Iressa 59 ATL# [001] 59 SNT MC# 59 Laquinimod 59 Phase III HEAT 59 Hedgehog inhibitor 59 Velcade bortezomib 59 genotypic resistance 59 Phase III AFFIRM 59 FOLPI 59 OvaRex ® MAb 59 visilizumab 59 GATTEX ® 59 mitogen activated ERK kinase 59 BCX# 59 myelofibrosis polycythemia vera 59 TRX1 59 palifosfamide 59 antiretroviral naïve 59 CA9 SCAN 59 pharmacokinetic PK profile 59 Ketotransdel 59 oral talactoferrin 59 Glybera 59 Dapagliflozin 59 atherosclerosis regression 59 Enzastaurin 59 R# #mg BID 59 somatostatin analog 59 TLK# 59 immunotherapeutic approaches 59 lorvotuzumab mertansine 59 bortezomib Velcade 59 FavId 59 trastuzumab 59 Prestara TM 59 Teriflunomide 59 Panzem R 59 GOUT 59 NovoTTF 59 B CLL 59 NeuVax 59 StemEx 59 relapsed leukemia 59 xenograft models 59 Forodesine HCl 59 relapsed MCL 59 Tavocept 59 ASCO GI 59 vinca alkaloid 59 registrational Phase 59 Theratope 59 cell lymphoma CTCL 59 iclaprim 59 APTIVUS 59 virus HCV protease inhibitor 59 Randomized controlled 59 EDEMA3 trial 59 GVAX ® 59 trastuzumab Herceptin ® 59 dextromethorphan quinidine 59 BEXXAR Therapeutic Regimen 59 Phase 1b trial 59 Primary endpoints 59 TroVax ® 59 metastatic malignant 59 HIF PHI 59 Seliciclib 59 GeoVax vaccine 59 RNAi Therapeutic 59 S/GSK# 59 phase IIb study 59 phase IIb trial 59 CUSTOM III 59 visceral metastases 59 taxane refractory 59 phase Ib clinical 59 peritoneal carcinomatosis 59 humanised monoclonal antibody 59 PKC# 59 Tovaxin TM 59 motesanib diphosphate 59 relapsing remitting MS RRMS 59 oncolytic virus therapies 59 FDG PET imaging 59 Phase III randomized controlled 59 radezolid 59 Combidex 59 IMC A# 59 dexanabinol 59 recurrent metastatic ovarian cancer 59 Zybrestat 59 registrational trial 59 ON #.Na 59 florbetaben 59 Elagolix 59 GetGoal Phase III 59 blinded randomized placebo controlled 59 concurrent chemoradiation 59 Confirmatory 59 anti leukemic 59 Carfilzomib 59 oral rivaroxaban 59 OncoVex 59 mTOR inhibitors 59 Targretin capsules 59 neoadjuvant treatment 59 HER2 positive cancers 59 lung pancreatic 59 Cloretazine R 59 EOquin TM 59 platinum refractory 59 Daclizumab 59 HRPC 59 ENDEAVOR III 58 Pimavanserin 58 ACAPODENE TM 58 KRAS mutations occur 58 Accelerated Partial Breast Irradiation 58 aplindore 58 ENRICH trial 58 #I TM# 58 anastrazole 58 Ataluren 58 CB2 selective receptor agonist 58 evaluating Prochymal 58 fluoropyrimidine 58 pediatric acute lymphoblastic 58 MERLIN TIMI 58 advanced metastatic renal 58 GERD migraine headaches 58 ganaxolone 58 metastatic castrate resistant 58 NATRECOR R 58 MediGene focuses 58 methotrexate therapy 58 baminercept 58 EOquin 58 TOCOSOL Paclitaxel 58 MET inhibitor 58 #rd Annual CTRC 58 PLK1 SNALP 58 prospectively defined 58 canakinumab 58 sNDA submission 58 viral kinetic 58 entinostat 58 patients receiving myelosuppressive 58 Maximum Tolerated Dose MTD 58 DEEP AF 58 LymphoStat B 58 INCB# [003] 58 Nuvion 58 follicular Non Hodgkin 58 SCCHN 58 FOLOTYN ® 58 GALNS 58 myeloproliferative disorders 58 ularitide 58 anthracycline taxane 58 medically inoperable 58 Ambrisentan 58 histological subtype 58 P#X# antagonist 58 non metastatic osteosarcoma 58 EMPOWER TM 58 cytotoxic therapy 58 basal bolus regimen 58 gemcitabine Gemzar ® 58 hypoxia activated prodrug 58 prospective multicentre 58 LibiGel ® 58 Beta catenin pathway 58 incyclinide 58 hormone receptor negative 58 PRIMO CABG2 58 Denufosol 58 tumor histology 58 SCH # 58 PREOS 58 torezolid phosphate 58 docetaxel Taxotere R 58 Taxotere chemotherapy 58 Doxil ® 58 OHR/AVR# 58 #th Annual Interscience 58 paclitaxel eluting stents 58 haematological cancers 58 TASKi2 58 Immunotherapeutic 58 Myelodysplastic syndromes MDS 58 BRAF inhibitor 58 Voreloxin 58 T1c 58 abiraterone acetate 58 lymphoma CTCL 58 vivo toxicology 58 successfully commercialize Iluvien 58 Stedivaze 58 oral proteasome inhibitor 58 gastrointestinal stromal tumor GIST 58 Omacetaxine 58 ZACTIMA 58 antiangiogenic agents 58 efficacy tolerability 58 locoregional 58 Evoltra ® 58 Vectibix monotherapy 58 metastatic renal cell 58 Prosaptide 58 hA# 58 ENDEAVOR IV 58 ImmunoVEX HSV2 58 TEMSO 58 omacetaxine mepesuccinate 58 Ozarelix 58 GRNOPC1 contains 58 sarcoma melanoma 58 Advaxis Phase 58 obatoclax 58 recombinant PSMA vaccine 58 EchoCRT 58 TOLAMBA 58 CA4P 58 alkylating agent 58 cetuximab Erbitux R 58 Phase 2a trial 58 Fodosine 58 letrozole Femara 58 unresectable tumors 58 Dasatinib 58 AGILECT R 58 Amoxicillin PULSYS Phase III 58 GSK # 58 esophageal carcinoma 58 NSABP C 58 temsirolimus 58 azilsartan medoxomil 58 predictive biomarker 58 multiple myeloma MM 58 bardoxolone 58 thymalfasin 58 Hormone Refractory Prostate Cancer 58 Randomized Phase 58 Atrasentan 58 chemotherapeutic agent 58 adjuvant therapy 58 ARCOXIA 58 Phase Ib clinical trials 58 Vaxfectin TM 58 GMX# 58 blinatumomab 58 CHAMPION PCI 58 Pivotal Phase III 58 rxRNA 58 optimal dosing 58 Amrubicin 58 APEX AMI 58 Combination REOLYSIN R 58 Tocosol Paclitaxel 58 XL# XL# XL# 58 ara C 58 Achieves Primary Endpoint 58 SPIRIT FIRST 58 NeuroStar TMS Therapy 58 ARIKACE ™ 58 sunitinib Sutent 58 Prestara 58 dasatinib Sprycel 58 TransVax tm 58 Genasense ® 58 Phase #b/#a 58 trodusquemine 58 talabostat 58 eculizumab 58 HGS ETR1 mapatumumab 58 Peginterferon alfa 2b 58 APTIVUS r 58 Cutaneous T 58 Combo Stent 58 ataluren 58 CANCIDAS 58 metastatic malignant melanoma 58 including eniluracil ADH 58 mCRC patients 58 brivaracetam 58 castrate resistant 58 prokinetic agent 58 drug conjugate 58 Panzem NCD 58 Trastuzumab DM1 58 Onconase 58 anti angiogenic agents 58 bevacizumab Avastin ® 58 LibiGel ® testosterone gel 58 Pertuzumab 58 radiochemotherapy 58 DEB# 58 antibody MT# 58 Phase III confirmatory 58 Tarvacin Anti Cancer 58 Bicifadine 58 Aryplase 58 resistant ovarian cancer 58 Pyridorin 58 DCVax ® 58 ancrod 58 hoFH 58 tesmilifene 58 prostatic adenocarcinoma 58 Neulasta ® 58 intravesical infusion therapy 58 TYZEKA 58 stage IIIB 58 biliary tract cancer 58 hematological parameters 58 phase IIIb 58 Xcytrin R 58 Pemetrexed 58 CALGB # [001] 58 essential thrombocythemia ET 58 K ras 58 apremilast 58 allogeneic stem cell 58 DAPT 58 Zarnestra 58 Folfox 58 initiated Phase 1b 58 custirsen 58 Plicera 58 therapeutic regimens 58 PrevOnco ™ 58 Vicriviroc 58 MYDICAR 58 Gleevec resistant 58 Vascular Wrap 58 NEUMUNE 58 ALN HPN 58 Multiple Myeloma MM 58 paclitaxel Taxol R 58 Taxotere ® 58 eprotirome 58 LEP ETU 58 MEK inhibitors 58 SYNTAX trial 58 velafermin belinostat 58 Antisoma AS# 58 myelodysplastic myeloproliferative diseases 58 smoldering multiple myeloma 58 REMINYL ® 58 PRECISE trial 58 delipidation 58 Dendreon Provenge 58 Protexia R 58 localized renal 58 pegylated liposomal doxorubicin PLD 58 HuMax CD#b 58 ALN VSP 58 invasive lobular carcinoma 58 recurrent ovarian 58 EMPOWER ™ 58 Troxatyl 58 unique alkylating agent 58 VELCADE melphalan 58 hematopoietic cancers 58 CLL SLL 58 BiTE 58 vandetanib 58 R#/MEM # 58 CHOP chemotherapy 58 doxorubicin HCl liposome injection 58 oral deforolimus 58 PF # [002] 58 AVE# 58 DCVax ® Brain 58 Thalomid ® 58 erythropoietic 58 Insegia 58 pharmacodynamics PD 58 myelofibrosis MF 58 Phase IIB clinical 58 pharmacokinetics PK 58 lucinactant 58 differentiated thyroid 58 KRAS status 58 cellular immunotherapy 58 Asentar 58 DermaVir Patch 58 endometrial adenocarcinoma 58 Phase IIb trials 58 Aurora kinase 58 relapsed SCLC 58 immunotherapeutic vaccine 58 vinorelbine tartrate 58 teduglutide 58 Cleviprex TM clevidipine 58 clinico pathological 58 Targretin 58 LUX Lung 58 lupus nephritis 58 Polyp Prevention Trial 58 hematological cancers 58 chemoresistant 58 imatinib resistant 58 Reverset 58 radiotherapy RT 58 ABSORB trial 58 clinically localized prostate 57 MYDICAR ® 57 phase IIb 57 Therapeutics TCT scientific 57 ICON7 57 phase IIa 57 ALN PCS 57 Thiovir 57 VNP#M 57 isoform selective